[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Skolkovo Institute of Science and Technology\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":154},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,43,73,106,135],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100601438","study-of-visual-perception-phenomena-phosphene-mapping-induced-by-tms-and-its-relationship-with-eye-movements-100601438",false,"NCT07110493","Study of Visual Perception Phenomena: Phosphene Mapping Induced by TMS and Its Relationship With Eye Movements","Inclusion Criteria:\n\nFor the \"Patients with Visual Snow Syndrome\" Arm:\n\nConfirmed diagnosis of Visual Snow Syndrome according to the International Classification of Headache Disorders, 3rd edition (ICHD-3) criteria.\n\nPresence of persistent, dynamic, tiny dots (\"visual snow\") across the entire visual field.\n\nPresence of at least one of the following additional visual symptoms:\n\nPalinopsia (prolonged afterimages). Photophobia (hypersensitivity to light). Nyctalopia (impaired night vision). Blurred vision. Patients whose symptoms appeared after a SARS-CoV-2 viral illness may be included.\n\nFor the \"Color-blind Participants\" Arm:\n\nPresence of a color perception disorder. Must have a formal diagnosis of color blindness confirmed by specific ophthalmologic tests (e.g., Ishihara, Rabkin, Justova, or Stilling polychromatic plates, or the Farnsworth-Munsell test).\n\nFor the \"Healthy Controls\" Arm:\n\nAbsence of any active or past neurological, psychiatric, or ophthalmological disorders.\n\nExclusion Criteria:\n\nGeneral Criteria (Applicable to all participants):\n\nUse of psychotropic drugs. Any contraindications to Transcranial Magnetic Stimulation (TMS), such as a history of epilepsy, seizures, or metallic implants in the head.\n\nPregnancy.\n\nSpecific to the \"Patients with Visual Snow Syndrome\" Arm:\n\nPresence of any organic abnormalities in the eyes or visual system identified during a standard ophthalmologic examination.\n\nPresence of comorbid psychiatric disorders or other medical conditions (e.g., migraine with aura) that could explain the symptoms.\n\nSpecific to the \"Color-blind Participants\" Arm:\n\nAny non-congenital cases of color blindness. Presence of concomitant visual impairments that could affect visual perception independently of color blindness, such as cataracts, glaucoma, or macular degeneration.\n\nPresence of concomitant neurological or psychiatric diseases, such as schizophrenia, epilepsy, or mood disorders, that could affect the study results.",true,"ALL","18 Years","65 Years",{"count":20,"type":21},50,"ESTIMATED","INTERVENTIONAL",[24],"NA","The purpose of this basic science study is to better understand human visual perception. Phosphenes are flashes of light that can be induced using Transcranial Magnetic Stimulation (TMS). The location of these phosphenes is known to change with eye movements, but the exact influence of these movements is not fully understood.\n\nThe main questions this study aims to answer are:\n\nHow does stimulating specific areas of the visual cortex relate to where a person perceives a phosphene? How do eye movements affect the accuracy of mapping these sensations? The study will enroll three groups of adults (aged 18-65): patients with Visual Snow Syndrome, color-blind participants, and healthy volunteers.\n\nDuring the experiment, participants will receive single-pulse TMS to their visual cortex. Simultaneously, their eye movements will be monitored with an eye-tracker, and their brain activity will be recorded with EEG. Participants will be asked to report the location of the perceived light flashes. This will help create a map of the brain areas responsible for visual sensations and clarify how eye movements influence this process.",[27,28,29],"Visual Snow Syndrome","Color Blindness","Healthy Volunteer","RECRUITING","2025-07-31",{"date":33,"type":34},"2025-08-07","ACTUAL",{"date":36,"type":21},"2025-09-10",{"date":38,"type":21},"2026-12-10",{"name":40,"class":41},"Skolkovo Institute of Science and Technology","OTHER",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":49,"targetDuration":4,"studyType":22,"phases":51,"briefSummary":52,"conditions":53,"keywords":55,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":42},"100578641","peripheral-magnetic-stimulation-pms-effects-on-somatosensory-perception-in-patients-with-upper-limb-amputation-100578641","NCT06813937","Peripheral Magnetic Stimulation (PMS) Effects on Somatosensory Perception in Patients with Upper Limb Amputation","For Healthy Volunteers:\n\nInclusion Criteria:\n\n1. Availability of signed written informed consent.\n2. Absence of somatic and psychiatric diseases (more details in the exclusion criteria)\n3. Ability and willingness to comply with the requirements of this protocol. Inclusion Criteria\n\nExclusion Criteria:\n\n1. History of epilepsy (participant, participant's close relatives)\n2. Presence of metal or\u002Fand electric stimulators and\u002For implants in participant's body\n3. Presence of psychiatric disorders (including a history of), severe depression, suicidal tendencies, or a history of suicide attempts.\n4. History of cancer.\n5. Complicated traumatic brain injury (TBI) or a history of stroke.\n6. Drug addiction (including a history of).\n7. Congenital anomaly of upper limb development.\n8. Anomalies in the development of the central and peripheral nervous systems.\n9. Pregnancy\n\nFor stroke patients:\n\n1. History of epilepsy (participant, participant's close relatives)\n2. Presence of metal or\u002Fand electric stimulators and\u002For implants in participant's body\n3. Presence of psychiatric disorders (including a history of), severe depression, suicidal tendencies, or a history of suicide attempts.\n4. History of cancer.\n5. Complicated traumatic brain injury (TBI) or a history of stroke.\n6. Drug addiction (including a history of).\n7. Congenital anomaly of upper limb development.\n8. Anomalies in the development of the central and peripheral nervous systems.\n9. Pregnancy\n10. Presence of severe somatic pathology\n11. Presence of severe orthopedic deformity in the limb above the level of amputation.\n12. Purulent-septic pathology.",{"count":50,"type":21},30,[24],"The study investigates the capabilities of peripheral magnetic stimulation (PMS) as a tool for creating somatosensory sensations of various submodalities and analyzing the dynamics of bioelectric signals of the brain (using encephalography (EEG)) in healthy participants and participants with upper limb amputations. During the experiment, the participants' subjective sensations and EEG activity are recorded in response to magnetic pulses of varying intensity. In addition, the continuous PMS stimulation protocol and its effect on phantom sensations in participants with amputations will be tested for subsequent implementation in clinical practice.",[54],"Phantom Limb Pain",[56,57,58,59,60,61,62,63,64],"Neuromodulation","Phantom limb pain","Neuropathic pain","Neurostimulation","Chronic pain","Peripheral magnetic stimulation","PMS","Amputation","Amputees","2025-02-03",{"date":67,"type":34},"2025-02-07",{"date":69,"type":34},"2024-09-16",{"date":71,"type":21},"2027-09-16",{"name":40,"class":41},{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":4,"eligibilityCriteria":79,"healthyVolunteers":15,"sex":16,"minAge":80,"maxAge":81,"enrollmentInfo":82,"targetDuration":4,"studyType":84,"phases":4,"briefSummary":85,"conditions":86,"keywords":90,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":105},"100578061","study-of-hemodynamic-markers-of-upper-extremity-motor-dysfunction-in-stroke-patients-using-functional-near-infrared-spectroscopy-fnirs-100578061","NCT06806397","Study of Hemodynamic Markers of Upper Extremity Motor Dysfunction in Stroke Patients Using Functional Near Infrared Spectroscopy (fNIRS)","Studying the Mechanisms of Visual-motor Transformation to Find Neurophysiological Markers of Altered Functions of Cortical Motor Circuits in Patients with Neurological Disorders and Developing Technologies for Their Rehabilitation.","For Healthy Volunteers:\n\nInclusion Criteria:\n\n1\\. Availability of signed written informed consent. 3. Absence of somatic and psychiatric diseases (more details in the exclusion criteria) 4. Ability and willingness to comply with the requirements of this protocol.\n\nExclusion Criteria:\n\n1. The presence of superficial injury of head (S00-S09 International Classification of Diseases 10 (ICD-10).\n2. The presence of mental, behavioural disorders (F00-F99 ICD-10).\n3. Drug addiction in the past or at the moment.\n4. The presence of diseases of the nervous system (G00-G99 ICD-10).\n5. . History of intracranial injury (S06 ICD-10) or stroke (I64 ICD-10).\n6. The presence of somatoform disorders (F45 ICD-10).\n7. Any conditions that, in the opinion of the Investigator, meet the exclusion criteria\n8. Presence of electrical and\u002For metallic implants or stimulants in the body (eg, implanted deep brain stimulation devices, pacemakers, hearing aids and cochlear implants, intracranial metal implants).\n9. Pregnancy\n10. The presence of malignant neoplasms (C00-C97 ICD-10).\n\nFor stroke patients:\n\nInclusion Criteria:\n\n1. Signed written informed consent.\n2. People after the first acute cerebrovascular accident (CVA), early or late rehabilitation period.\n3. The level of severity of paresis of the upper limb from 3 points to 0 (according to a 6-point neurological scale)\n4. The minimum visual acuity is not lower than 0.2 on the Sivtsev scale.\n5. The ability and willingness of the patient to comply with the requirements of this protocol.\n6. Expressed patient motivation for rehabilitation.\n\nExclusion Criteria:\n\n1. Severe cognitive impairment (\\\u003C10 points according to the Montreal Cognitive Assessment Scale).\n2. Hamilton score above 18 points.\n3. The score on the Rankin scale is above 4 points.\n4. Associated neurological disorders that cause decreased muscle strength or increased muscle tone in the upper limbs (eg, cerebral palsy, brain damage from trauma) or stiffness (eg, Parkinson's disease, contracture).\n5. Late stages of arthritis or clinically significant limitation of passive range of motion in any of the joints studied in the study due to other reasons.\n6. The absence of a part of the upper limb due to amputation caused by various reasons.\n7. Any medical condition, including mental illness or epilepsy, that may affect the interpretation of study results, study conduct, or patient safety.\n8. Alcohol abuse, medical marijuana use, or recreational drug use in the 12 months prior to Visit 1.\n9. Use of experimental drugs or medical devices within 30 days prior to Visit 1.\n10. Lack of ability to follow study procedures, in the opinion of the investigator.\n11. The severity of the patient's condition according to the neurological or somatic status, which does not allow full rehabilitation.\n12. Severe visual disturbances, minimal visual acuity less than 0.2 Sivtsev visual acuity table.\n13. Unstable angina and\u002For heart attack within the previous month\n14. Repeated stroke.\n15. Severe unilateral spatial neglect.\n16. Uncontrolled arterial hypertension\n17. Ataxia\n18. All forms of epilepsy","35 Years","70 Years",{"count":83,"type":21},40,"OBSERVATIONAL","The aim of the study was to explore potential pathways for recovery and adaptation of the motor cortex by examining cerebral blood flow characteristics and hemodynamic markers analyzed by functional near-infrared spectroscopy (fNIRS) in patients with hemiparesis after stroke. Participants in the study performed a simple stimulus-response task several times with one healthy and one paralyzed limb at different stages of basic rehabilitation. A group of healthy, age-matched volunteers participated in the same experiment to verify the stroke-related changes. The researchers recorded fNIRS signals, muscle activity using electromyography, and heart activity using electrocardiography.",[87,88,89],"Stroke","Stroke with Hemiparesis","Stroke, Ischemic",[91,92,93,94,95,96],"stroke","hemiparesis","hemodynamics","fNIRS","restoration of motor function","Neurovascular coupling","2025-01-28",{"date":99,"type":34},"2025-02-04",{"date":101,"type":34},"2024-06-26",{"date":103,"type":21},"2025-04",{"name":40,"class":41},2,{"id":107,"slug":108,"hasResults":11,"nctId":109,"briefTitle":110,"officialTitle":110,"acronym":4,"eligibilityCriteria":111,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":112,"targetDuration":4,"studyType":22,"phases":113,"briefSummary":114,"conditions":115,"keywords":116,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":127,"lastUpdatePostDateStruct":128,"startDateStruct":130,"completionDateStruct":132,"leadSponsor":134,"locationsCount":105},"100570104","evaluation-of-neuroprosthesis-with-sensory-feedback-for-modulation-of-phantom-limb-pain-and-enhancing-quality-of-life-100570104","NCT06702904","Evaluation of Neuroprosthesis with Sensory Feedback for Modulation of Phantom Limb Pain and Enhancing Quality of Life","Inclusion Criteria:\n\n* Amputation of the upper limb at the level of the forearm or upper arm, or amputation of the lower limb at the level of the lower leg or thigh.\n* Age between 18 and 65 years.\n* Duration since amputation is at least 6 months.\n* Presence of persistent chronic pain syndrome rated between 4 and 10 on the Visual Analog Scale (VAS).\n* Absence of pregnancy at the time of implantation, confirmed by a pregnancy test (for female participants only).\n* Signed consent to participate in the study.\n\nExclusion Criteria:\n\n* Presence of severe somatic pathology that hinders surgical treatment and participation in the study.\n* Presence of psychiatric disorders (including a history of), severe depression, suicidal tendencies, or a history of suicide attempts.\n* Presence of severe orthopedic deformity in the limb above the level of amputation.\n* History of cancer.\n* History of epilepsy.\n* Complicated traumatic brain injury (TBI) or a history of stroke.\n* Inability to undergo electrostimulation due to other somatic pathology.\n* Purulent-septic pathology.\n* Drug addiction (including a history of).\n* Congenital anomaly of upper limb development.\n* Anomalies in the development of the central and peripheral nervous systems.",{"count":20,"type":21},[24],"This clinical trial is designed to assess the effectiveness of advanced neuromodulation techniques in reducing phantom limb pain by improving sensory feedback in bionic prostheses. The study will explore the use of Peripheral Nerve Stimulation to evaluate their impact on pain relief and sensory restoration. The trial aims the development of neuroprostheses that can provide sensory feedback through stimulation.",[54],[56,57,58,59,60,117,118,119,120,121,122,123,63,124,125,126],"Peripheral nerve stimulation","PNS","Spinal cord stimulation","SCS","Dorsal root ganglion stimulation","DRG","Cortical stimulation","Neurotechnology","Neuroprosthetics","BCI","2024-11-21",{"date":129,"type":34},"2024-11-25",{"date":131,"type":21},"2024-12-01",{"date":133,"type":21},"2029-05-01",{"name":40,"class":41},{"id":136,"slug":137,"hasResults":11,"nctId":138,"briefTitle":139,"officialTitle":140,"acronym":4,"eligibilityCriteria":111,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":141,"targetDuration":4,"studyType":22,"phases":142,"briefSummary":143,"conditions":144,"keywords":145,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":147,"lastUpdatePostDateStruct":148,"startDateStruct":150,"completionDateStruct":152,"leadSponsor":153,"locationsCount":105},"100565640","study-of-phantom-limb-pain-suppression-using-neuromodulation-methods-100565640","NCT06644807","Study of Phantom Limb Pain Suppression Using Neuromodulation Methods","Neuromodulation Methods for Suppressing Phantom Limb Pain",{"count":20,"type":21},[24],"This study assesses the effectiveness of neuromodulation in alleviating pain through the stimulation of peripheral nerves. The research involves implanting electrodes for test stimulation of peripheral nerves (PNS - Peripheral Nerve Stimulation), spinal cord (SCS - Spinal Cord Stimulation), dorsal root ganglia (DRGS - Dorsal Root Ganglion Stimulation), and motor cortex (MCS - Motor Cortex Stimulation). The study aims to explore the use of neuromodulation for pain relief in patients experiencing pain due to upper or lower limb amputation.",[54],[56,57,58,59,60,117,118,119,120,121,122,123,63,64,146],"Upper-limb injury","2024-10-14",{"date":149,"type":34},"2024-10-16",{"date":151,"type":34},"2024-09-01",{"date":133,"type":21},{"name":40,"class":41},""]